Past Issues
See what you've been missing. Browse every issue of our free, daily briefing.
The first CAR-T for solid tumors is here, and it didn't come from the West
A decade-long wall in cancer therapy just cracked: the world's first CAR-T approval for solid tumors landed in China, not the U.S. Meanwhile, Big Pharma went on a $22 billion shopping spree in a single week, and a gene-editing pioneer that once commanded billions in partnerships got sold for parts.
For the first time ever, a drug fights childhood diabetes itself, not just its symptoms
The FDA just cracked open a century-old treatment paradigm for type 1 diabetes, while Pfizer's $43 billion Seagen bet produced its first big flop. Meanwhile, the agency is quietly beta-testing a new operating system for how it watches clinical trials unfold. Big day.
Novo's Lilly-killer just lost the fight. Billions in market cap, gone.
Novo Nordisk built its next-gen obesity drug to dethrone Eli Lilly's tirzepatide. It couldn't even prove it was "basically just as good." That head-to-head loss, plus a $10.9 billion acquisition, an LSD pill posting jaw-dropping depression data, and a record-breaking M&A spree make this one of the most consequential days in biotech this year.
This cancer drug plays dead in your bloodstream (then wakes up at the tumor)
A $1.7 billion deal just validated one of the cleverest drug designs in oncology: a cancer therapy with molecular safety pins that only come off inside the tumor. Meanwhile, the most watched gene therapy in rare disease is fighting for survival after a Phase III miss and 500 layoffs.
Hackers lived inside Novo Nordisk for two months. Then they got greedy.
A hacking group says it stole Novo Nordisk's AI models, drug formulas, and clinical trial data, then demanded $25 million. The world's biggest pharma company refused to pay. Meanwhile, the obesity drug wars are escalating on three continents, and pharma just pledged $300 billion to avoid a single tax.
The first drug that destroys its target just got FDA approval
A drug class that spent 25 years in scientific purgatory just landed on a prescription bottle, and the ripple effects will reshape how the entire industry designs medicines. Meanwhile, a personalized cancer vaccine held strong for five full years, a gene-editing shot matched a lifetime of cholesterol pills, and a blockbuster blood test hit a wall it didn't see coming.
GSK just spent $10.6B to un-quit cancer
GSK abandoned oncology five years ago. Now it's writing one of the biggest checks in cancer M&A history to get back in, with two FDA-reviewed lung cancer drugs and a patent cliff breathing down its neck. Meanwhile, scientists finally cracked one of neuroscience's hardest problems, an entire antibiotic class escaped the IV pole, and the M&A feeding frenzy rolled on.
The FDA said no, then yes, then no, then yes to this gene therapy
The FDA reversed itself twice in 18 months on a Huntington's gene therapy, and the final answer could reshape the approval bar for every brain disease drug in the pipeline. Meanwhile, BioNTech swallowed its biggest mRNA rival, Medicare's "temporary" weight-loss drug benefit looks permanent, and a biotech turned its failed trial into an AI goldmine.
Colorado can now buy drugs from Canada. Good luck actually getting them.
The FDA just handed Colorado a historic permission slip to import prescription drugs from Canada, but the real obstacles are only beginning. Meanwhile, billions of dollars are flying in autoimmune M&A, a CRISPR therapy is rewriting the HAE playbook, and Medicare wants to close a loophole worth tens of billions.
A tiny protein just cost Gilead $7.8 billion (and might be worth every penny)
Gilead wrote a massive check for a synthetic protein the size of a molecule's fingernail, and the clinical data backing the deal is borderline absurd. Meanwhile, a pill nearly doubled survival in pancreatic cancer, Biogen went shopping for eyeballs, and a blood thinner finally figured out how to stop causing bleeding.
Prostate cancer just got its first precision therapy. Breast cancer did this 25 years ago.
The FDA just handed prostate cancer something breast cancer has had for a generation: a targeted drug matched to a specific genetic defect. Meanwhile, Lilly's $2.3 billion gamble on an untested blood cancer drug is already showing signs of life, and the obesity drug wars just got a whole lot clearer after a blockbuster week at ADA 2026.
The FDA just named names in its war on cheap Ozempic knockoffs
The FDA went full enforcement mode on compounded GLP-1 drugs, calling out Hims & Hers by name and threatening seizures. Meanwhile, Roche crashed the obesity party with a weight-loss number that has Eli Lilly looking over its shoulder.
Novo's next-gen obesity drug just lost the one fight it couldn't afford to lose
Novo Nordisk's CagriSema was supposed to dethrone Zepbound. Instead, it got dethroned. That head-to-head loss is the headline, but today's newsletter is stacked: Takeda's $4 billion acquisition bet just paid off spectacularly, Genentech fired a scientific legend, and the FDA is dismantling the cheap Ozempic market one warning letter at a time.
A biotech you've never heard of just raised $670M in the largest VC-backed IPO ever
A Cambridge cancer biotech most people couldn't name walked onto the Nasdaq and shattered every IPO record in the book, one day after landing a $2.3 billion Regeneron deal. Meanwhile, Takeda embarrassed Bristol Myers in a head-to-head psoriasis showdown, Novo's top scientist admitted the quiet part out loud about Lilly's obesity lead, and scientists discovered your Ozempic might be growing a tiny antidepressant factory in your gut.
The "undruggable" cancer target just got cracked: survival nearly doubled
A gene that scientists called untouchable for 40 years just produced one of the most jaw-dropping survival results in recent oncology history. That's just the opener: today's issue covers a two-in-one drug that beat immunotherapy's gold standard, the Pentagon dropping a bomb on biotech's biggest supplier, and evidence that Ozempic might fight cancer.
GSK just wrote a $10.6B check for two cancer drugs that don't exist yet
GSK is betting its next decade on two unapproved lung cancer drugs, and the price tag has Wall Street wincing. Meanwhile, a dead-on-arrival HIV pill just posted Phase 3 results, pancreatic cancer got a 92% response rate nobody expected, and kids with diabetes can finally skip the needle.
Roche just paid $700M for a drug that destroys proteins instead of blocking them
Roche dropped the biggest check in targeted protein degradation history, and it might mark the moment this entire drug class graduated from lab experiment to real medicine. Meanwhile, a Shanghai biotech just got the green light for something CAR-T has never pulled off: a randomized trial in solid tumors.
Novo's secret weapon lost the obesity Super Bowl. Stock cratered ~16%.
Novo Nordisk's next-gen obesity drug CagriSema was supposed to dethrone Zepbound. Instead, it lost the head-to-head trial and wiped out years of stock gains in a single day. Meanwhile, ADA 2026 turned into a full-blown arms race, with Lilly, Pfizer, and Roche all unveiling new weight-loss data that's pushing the market into uncharted territory.
The first drug that destroys its target just got FDA approval
A 25-year-old scientific idea just became a real prescription. The FDA approved the first-ever PROTAC drug, a molecule that tricks cancer cells into shredding their own growth machinery. Meanwhile, a $4 semaglutide syringe launched in India, Roche accused Washington of "cold-blooded blackmail," and a single lawsuit wiped out an entire year of Takeda's profit.
The Supreme Court just blew open the door for cheaper generics
The highest court in the land unanimously told brand drugmakers to stop suing generics for following the rules Congress wrote. Meanwhile, the FDA wants to watch your clinical trial like a live sports broadcast, and a new bill could make your China biotech deal illegal overnight.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.